Disease · MONDO_0000521

salivary gland carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. salivary gland carcinoma. Diseases, record MONDO_0000521. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000521

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: salivary gland carcinoma; Open Targets
Open Targets ID: MONDO_0000521; Open Targets
Other names: carcinoma of saliva-secreting gland, carcinoma of salivary gland, carcinoma of the salivary gland, saliva-secreting gland carcinoma; Open Targets
Disease Ontology: DOID:0050904; Disease Ontology
NCI Thesaurus: C9272; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 43 of its 45 drugs, from ClinicalTrials.gov; Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ELRAGLUSIB	CHEMBL483465	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GOSERELIN	CHEMBL1201247	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IVONESCIMAB	CHEMBL6068451	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LAROTRECTINIB	CHEMBL3889654	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TRASTUZUMAB DERUXTECAN	CHEMBL4297844	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ABIRATERONE	CHEMBL254328	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ALPELISIB	CHEMBL2396661	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets49

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AR	Androgen receptor	6	Androgen Receptor agonist; Androgen Receptor antagonist	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	6	Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	5	Gonadotropin-releasing hormone receptor agonist	Phase 2	https://conductscience.org/library/genes/2798	Drugs and targets
TUBA1A	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 49

See all 49 targets

Trials19

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02879162	Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours	Phase 2	140	2025-02-17	Advanced Rare Tumours	DURVALUMAB, TREMELIMUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03383692	Study of DS-8201a for Participants With Advanced Solid Malignant Tumors	Phase 1	40	2021-06-14	Neoplasm Metastasis	ITRACONAZOLE, RITONAVIR, TRASTUZUMAB DERUXTECAN	Its record names the disease	ClinicalTrials.gov
NCT04325828	A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma	Phase 2	31	2022-07-06	Salivary Gland Neoplasms	APALUTAMIDE, GONADORELIN, GONADORELIN ACETATE	Its record names the disease	ClinicalTrials.gov
NCT05192642	A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice		368		Solid Tumors Harboring NTRK Fusion	LAROTRECTINIB	Its record names the disease	ClinicalTrials.gov
NCT02576431	A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors	Phase 2	215		Solid Tumors Harboring NTRK Fusion	LAROTRECTINIB	Its record names the disease	ClinicalTrials.gov
NCT02776163	Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas	Phase 2	107		Salivary Gland Tumors, Head and Neck Cancer	DOCETAXEL, NEDAPLATIN	Its record names the disease	ClinicalTrials.gov
NCT03132038	Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck	Phase 2	98		Salivary Gland Carcinoma, Metastatic Cancer, Recurrent Cancer	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT05924256	A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing	Phase 2	88		Advanced Salivary Gland Carcinoma	LEUPROLIDE, TRASTUZUMAB REZETECAN	Its record names the disease	ClinicalTrials.gov
NCT02393820	Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma	Phase 2	72		Salivary Gland Carcinoma	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT05694819	Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)	Phase 2	57		Salivary Gland Cancer	DAROLUTAMIDE, GOSERELIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 19

See all 19 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort 1: DS-8201a + Ritonavir vs Cohort 2: DS-8201a + Itraconazole: deaths from any cause	1 of 17	0 of 23	40	NCT03383692	Trial comparisons
Cohort 1: DS-8201a + Ritonavir vs Cohort 2: DS-8201a + Itraconazole: serious adverse events	2 of 17	3 of 23	40	NCT03383692	Trial comparisons
Cohort 1: DS-8201a + Ritonavir vs Cohort 2: DS-8201a + Itraconazole: Objective Response Rate as Confirmed By The Investigator's Assessment in Participants With HER2-Expressing Advanced Solid Malignant Tumors	8 of 17	7 of 19	36	NCT03383692	Trial comparisons
Cohort 1: DS-8201a + Ritonavir vs Cohort 2: DS-8201a + Itraconazole: Objective Response Ratio (ORR) as Confirmed By The Investigator's Assessment in Participants With HER2-Expressing Advanced Solid Malignant Tumors	9 of 17	10 of 19	36	NCT03383692	Trial comparisons

Papers from its trials26

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39737219	RESULT	1	PubMed
42614029	DERIVED	1	PubMed
42579830	DERIVED	1	PubMed
42546251	DERIVED	1	PubMed
42129335	DERIVED	1	PubMed
41878954	DERIVED	1	PubMed
40341199	DERIVED	1	PubMed
40267388	DERIVED	1	PubMed
39886516	DERIVED	1	PubMed
39869835	DERIVED	1	PubMed

1 to 10 of 26

See all 26 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000521

GET https://conductscience.org/api/diseases/v1/MONDO_0000521/drugs?page=2

API reference For AI assistants